Shares of Eli Lilly (LLY) are trading higher Tuesday in response to a promising new study that found its weight-loss drug tirzepatide — marketed as GLP-1s Mounjaro and Zepbound — to significantly reduce long-term risks of developing Type 2 diabetes by 94%.

Catalysts anchors Seana Smith and Madison Mills break down the details.

For more expert insight and the latest market action, click here to watch this full episode of Catalysts.

This post was written by Angel Smith